Slow releace tablets of clarithromycin, and its preparing method

A technology for clarithromycin and sustained-release tablets, which is applied in the field of clarithromycin sustained-release tablets and its preparation, which can solve the problems of large gastrointestinal side effects, achieve small local irritation, reduce the incidence rate, and improve bioavailability Effect

Active Publication Date: 2007-07-25
HAINAN PULIN PHARMA +1
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, common preparations of clarithromycin have local irritation and large gastrointestinal side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] The plain tablet formula of clarithromycin sustained-release tablets is as follows:

[0026] 500mg

[0027] clarithromycin

[0028] Hydroxypropyl Methyl Cellulose 170mg

[0029] Polyvinylpyrrolidone (K30) 18mg

[0030] Magnesium Stearate 10mg

[0031] Talc powder 5mg

[0032] Lactose 175mg

[0033] Citric acid 100mg

[0034] The coating formula for clarithromycin sustained-release tablets is as follows:

[0035] Hydroxypropyl Methyl Cellulose 9.8mg

[0036] Propylene Glycol 4mg

[0037] Castor Oil 3.45mg

[0038] Polysorbate-80 3.9mg

[0039] Talc 8.5mg

[0040] Tartrazine 0.35mg

[0041] Titanium dioxide 2.4mg

[0042] The preparation method of above-mentioned clarithromycin sustained-release tablet is as follows:

[0043] 1. Dissolve 18 mg of polyvinylpyrrolidone (K30) in ethanol solution to prepare alcohol solution. Put clarithromycin 500mg, hydroxypropylmethylcellulose (100cp) 170mg, citric acid 100mg, and lactose 175mg that have p...

Embodiment 2

[0047] Changes in blood drug concentration (microgram / ml) after clarithromycin sustained-release tablet (500mg, single) and clarithromycin common tablet (250mg, twice a day) in the patient's oral embodiment 1

[0048] time

[0049] According to the research data, clarithromycin sustained-release tablets ensure sustained and slow release of the drug. Compared with ordinary tablets, the blood concentration is more stable. Higher bioavailability.

Embodiment 3

[0051] The plain tablet formula of clarithromycin sustained-release tablets is as follows:

[0052] 500mg

[0053] clarithromycin

[0054] Hydroxypropyl Methyl Cellulose 230mg

[0055] Polyvinylpyrrolidone (K30) 20mg

[0056] Magnesium Stearate 50mg

[0057] Lactose 225mg

[0058] Citric acid 187.5mg

[0059] The coating formula for clarithromycin sustained-release tablets is as follows:

[0060] Hydroxypropyl Methyl Cellulose 12.5mg

[0061] Propylene Glycol 6mg

[0062] Castor Oil 5mg

[0063] Polysorbate-80 5.25mg

[0064] Talc 6.25mg

[0065]Tartrazine 0.35mg

[0066] Titanium dioxide 2.4mg

[0067] The preparation method of the above-mentioned clarithromycin sustained-release tablet is as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A slowly-released tablet of clarithromycin contains proportionally clarithromycin, high-molecular adhesive, flow-assistant lubricant, pH regulator and sweetening agent. Its preparing process is also disclosed.

Description

technical field [0001] The invention relates to a clarithromycin sustained-release tablet and a preparation method thereof. Background technique [0002] Clarithromycin is a semi-synthetic macrolide antibiotic with the chemical name 6-O-methylerythromycin. Clarithromycin is obtained by methylating the 6-hydroxyl of erythromycin A. This change in chemical structure effectively inhibits its transformation reaction of self-dehydration and condensation under acidic conditions, thereby greatly improving the clarithromycin. Stability of mycomycin in the stomach. [0003] The active ingredient of the medicine is applied to various infections caused by various sensitive bacteria, especially upper and lower respiratory tract infections, skin and soft tissue infections, etc., and it can effectively improve the healing rate of ulcers when used in combination with other anti-ulcer drugs. Its indications: the treatment of pneumonia caused by Haemophilus influenzae, Haemophilus parainfl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K9/22A61P31/04
Inventor 范敏华
Owner HAINAN PULIN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap